Adult human mesenchymal stromal cells and the treatment of graft versus host disease

Stem Cells and Cloning: Advances and Applications

Volumn 7, Issue 1, 2014, Pages 45-52

  Herrmann, Richard P ^a   Sturm, Marian J ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Acute; Chronic; Graft versus host disease; Mesenchymal stromal cells

Indexed keywords

CORTICOSTEROID; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; BONE MARROW; CELL EXPANSION; CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); GOOD MANUFACTURING PRACTICE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LYMPHOCYTIC INFILTRATION; MESENCHYMAL STROMA CELL TRANSPLANTATION; MULTIPOTENT STEM CELL; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; QUALITY CONTROL; REVIEW;

EID: 84896896801     PISSN: None     EISSN: 11786957     Source Type: Journal    
DOI: 10.2147/SCCAA.S37506     Document Type: Review

References (72)

1. Ruhl H, Bein G, Sachs UJ. Transfusion-associated graft-versus-host disease. Transfus Med Rev. 2009;23:62-71.
2. Murphy J. The effect of adult chick organ graft on the chick embryo. J Exp Med. 1916;24:1-6.
3. Simonsen M. The impact on the developing embryo and newborn animal of adult homologous cells. Acta Pathol Microbiol Scand. 1957;40: 480-500.
4. Billingham RE, Brent L. Quantitative studies on tissue transplantation immunity. IV. Induction of tolerance in newborn mice and studies on the phenomenon of runt disease. Phil Trans R Soc B Biol Sci. 1959;242:439.
5. Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257:491-496.
6. Bortin MM. A compendium of reported human bone marrow transplants. Transplantation. 1970;9:571-587.
7. van Rood JJ, Oudshoorn M. Eleven million donors in bone marrow donors worldwide! Time for reassessment? Bone Marrow Transplant. 2008;41:1-9.
8. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966;62:21-78.
9. Sackstein R. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006;12(1 Suppl 1):2-8.
10. Deeg HJ, Antin JH. The clinical spectrum of acute graft-versus-host disease. Semin Hematol. 2006;43:24-31.
11. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15: 825-828.
12. Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood. 2013;121:585-594.
13. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8: 387-394.
14. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109: 4119-4126.
15. Martin PJ, Inamoto Y, Flowers ME, Carpenter PA. Secondary treatment of acute graft-versus-host disease: a critical review. Biol Blood Marrow Transplant. 2012;18:982-988.
16. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150-1163.
17. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068-1073.
18. Truitt RL. The Mortimer M. Bortin Lecture: to destroy by the reaction of immunity: the search for separation of graft-versus-leukemia and graft-versus-host. Biol Blood Marrow Transplant. 2004;10:505-523.
19. Toubai T, Sun Y, Reddy P. GVHD pathophysiology: is acute different from chronic? Best Pract Res Clin Haematol. 2008;21:101-117.
20. Sakoda Y, Hashimoto D, Asakura S, et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood. 2007;109:1756-1764.
21. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-956.
22. Socie G, Ritz J, Martin PJ. Current challenges in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010; 16(Suppl 1):S146-S151.
23. Fassil H, Bassim CW, Mays J, et al. Oral chronic graft-vs-host disease characterization using the NIH scale. J Dent Res. 2012; 91(Suppl 7):45S-51S.
24. Filipovich AH. Diagnosis and manifestations of chronic graft-versus-host disease. Best Pract Res Clin Haematol. 2008;21:251-257.
25. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.
26. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undif-ferentiated mesenchymal stem cells. Exp Hematol. 2003;31:890-896.
27. Bocelli-Tyndall C, Bracci L, Spagnoli G, et al. Bone marrow mesenchy-mal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford). 2007;46: 403-408.
28. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107:367-372.
29. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immuno-genic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006;108:2114-2120.
30. Spaggiari GM, Moretta L. Cellular and molecular interactions of mes-enchymal stem cells in innate immunity. Immunol Cell Biol. 2013;91: 27-31.
31. Choudhery MS, Badowski M, Muise A, Harris DT. Comparison of human mesenchymal stem cells derived from adipose and cord tissue. Cytotherapy. 2013;15:330-343.
32. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726-736.
33. Malgieri A, Kantzari E, Patrizi MP, Gambardella S. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med. 2010;3:248-269.
34. Kemp KC, Hows J, Donaldson C. Bone marrow-derived mesenchymal stem cells. Leuk Lymphoma. 2005;46:1531-1544.
35. Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica. 2007;92:1208-1215.
36. Spees JL, Gregory CA, Singh H, et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther. 2004;9:747-756.
37. Bernardo ME, Avanzini MA, Perotti C, et al. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol. 2007;211:121-130.
38. Fekete N, Gadelorge M, Furst D, et al. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identifca-tion of active components. Cytotherapy. 2012;14:540-554.
39. Fossett E, Khan WS. Optimising human mesenchymal stem cell numbers for clinical application: a literature review. Stem Cells Int. 2012;2012:465259.
40. Santos F, Andrade PZ, Abecasis MM, et al. Toward a clinical-grade expansion of mesenchymal stem cells from human sources: a microcarrier-based culture system under xeno-free conditions. Tissue Eng Part C Methods. 2011;17:1201-1210.
41. Khanal S, Tomlinson A. Tear physiology in dry eye associated with chronic GVHD. Bone Marrow Transplant. 2012;47:115-119.
42. Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L. Immunological characterization of multipotent mesenchymal stromal cells - The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy. 2013;15:1054-1061.
43. Prockop DJ. Defning the probability that a cell therapy will produce a malignancy. Mol Ther. 2010;18:1249-1250.
44. Casiraghi F, Remuzzi G, Abbate M, Perico N. Multipotent mesenchymal stromal cell therapy and risk of malignancies. Stem Cell Rev. 2013;9: 65-79.
45. von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mes-enchymal stromal cell therapy in humans indicate limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012;30: 1575-1578.
46. Lucchini G, Dander E, Pavan F, et al. Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation. Stem Cells Int. 2012;2012:690236.
47. Meisel R, Brockers S, Heseler K, et al. Human but not murine multipo-tent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia. 2011;25:648-654.
48. Wang J, Liao L, Wang S, Tan J. Cell therapy with autologous mesenchy-mal stem cells - how the disease process impacts clinical considerations. Cytotherapy. 2013;15:893-904.
49. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-1441.
50. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-1586.
51. ClinicalTrials.Gov. Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease. Osiris Therapeutics. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00366145?term=mesenchymal+stem+cells+AND+bone+marrow+transplantation&rank=16. Accessed December 22, 2013.
52. Galipeau J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013;15:2-8.
53. Kuzmina LA, Petinati NA, Parovichnikova EN, et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease - a Phase II study. Stem Cells Int. 2012;2012:968213.
54. Yang YG, Wang H, Asavaroengchai W, Dey BR. Role of interferon-gamma in GVHD and GVL. Cell Mol Immunol. 2005;2:323-329.
55. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386-398.
56. Krampera M. Mesenchymal stromal cell 'licensing': a multistep process. Leukemia. 2011;25:1408-1414.
57. Zhou H, Guo M, Bian C, et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant. 2010;16:403-412.
58. Weng J, He C, Lai P, et al. Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. Mol Ther. 2012;20:2347-2354.
59. Prockop DJ, Brenner M, Fibbe WE, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010;12:576-578.
60. Menard C, Pacelli L, Bassi G, et al. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev. 2013;22:1789-1801.
61. Fox JM, Chamberlain G, Ashton BA, Middleton J. Recent advances into the understanding of mesenchymal stem cell traffcking. Br J Haematol. 2007;137:491-502.
62. Yagi H, Soto-Gutierrez A, Parekkadan B, et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant. 2010;19:667-679.
63. Herrmann R, Sturm M, Shaw K, et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. Int J Hematol. 2012;95:182-188.
64. Forbes GM, Sturm MJ, Leong RW, et al. A Phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol. 2014;12:64-71.
65. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390-1397.
66. Fang B, Song Y, Liao L, Zhang Y, Zhao RC. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc. 2007;39: 3358-3362.
67. von Bonin M, Stolzel F, Goedecke A, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009;43:245-251.
68. Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009;15: 804-811.
69. Perez-Simon JA, Lopez-Villar O, Andreu EJ, et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica. 2011;96:1072-1076.
70. Muroi K, Miyamura K, Ohashi K, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol. 2013;98: 206-213.
71. Zhang LS, Liu QF, Huang K, Zhang Y, Fan ZP, Huang SL. Mesenchymal stem cells for treatment of steroid-resistant chronic graft-versus-host disease. Zhonghua Nei Ke Za Zhi. 2009;48:542-546. Chinese.
72. Weng JY, Du X, Geng SX, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010;45:1732-1740.